This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

PATIENT PROFILE 3Young professional female with persistent, uncontrolled itching and lesions that are impacting her workWho is the patient?

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.

  • ​​​​​​​British-Jamaican female, 23 years old
  • Disease and treatment history: AD since early childhood. Has tried several treatments, all with unsatisfactory results, including topical corticosteroids, TCI, phototherapy, ciclosporin and dupilumab 300 mg Q2W (EASI reduction of 50% achieved). Itching and visible lesions remain a persistent problem

  • Clinical assessment: EASI=27; 40% BSA (including hands, face, flexion points and torso); recent episodes of conjunctivitis
  • Personal impact: Constant itching causes distraction and sleep deprivation, which both impact her work (personal assistant at a law firm); concerned about losing her job
  • Preferences: Wants to scratch less and would prefer a high level of skin clearance 



Why consider Cibinqo (abrocitinib)?1.Cibinqo used in combination with topical therapy provides skin clearance at Week 12 in significantly more patients compared with placebo1,2JADE COMPARE (CO-PRIMARY ENDPOINTS, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)
Proportion of patients achieving IGA 0/1
Scroll left to view table
IGA 0/1 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 106/219 (48.8%; 41.8–55.0
Cibinqo 100 mg 86/235 (36.6%; 30.4–42.8)
Dupilumab 300 mg 88/241 (36.5%; 30.4–42.6)
Placebo 18/129 (14.0%; 8.0–19.9)

Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

Proportion of patients achieving EASI-75
Scroll left to view table
EASI-75 at Week 12
no./Total no. (%, 95% CI)
Cibinqo 200 mg
154/219 (70.3%; 64.3–76.4)
Cibinqo 100 mg
138/235 (58.7%; 52.4–65.0)
Dupilumab 300 mg
140/241 (58.1%; 51.9–64.3)
Placebo
35/129 (27.1%; 19.5–34.8)

Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

2.Cibinqo 200 mg provides superior itch response vs dupilumab at Week 21–3JADE COMPARE (KEY SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)Proportion of patients achieving PP-NRS4

PP-NRS4 is defined as an improvement of ≥4 points from baseline in the severity of PP-NRS. Cibinqo 200 mg was compared with dupilumab in a key secondary head-to-head endpoint at Week 2. This endpoint was further analysed as prespecified multiplicity-controlled analysis and showed superiority to dupilumab down to Day 4.

3.Cibinqo provides a high level of skin clearance1,3JADE COMPARE (SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)Proportion of patients achieving EASI-90
Scroll left to view table
EASI-90 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 101/219 (46.1%; 39.5–52.7)
Cibinqo 100 mg 86/235 (36.6%; 30.4–42.8)
Dupilumab 300 mg 84/241 (34.9%; 28.8–40.9)
Placebo 13/129 (10.1%; 4.9–15.3)

EASI-90 at all scheduled points are prespecified secondary endpoints not controlled for multiplicity; treatment differences could represent chance findings.

Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

4.Cibinqo reduces AD-related sleep loss1,3JADE COMPARE (SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)% reduction (improvement) in SCORAD sleep loss subscale at Week 12

Change from baseline in SCORAD sleep loss is a prespecified secondary endpoint not controlled for multiplicity, therefore treatment differences could represent chance findings.

​​​​​​​Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

Explore morePatient 4

Teenage competitive swimmer suffering with regular disease flares and itching.

View profileLoading
Patient 1

Unemployed male with increasingly uncontrolled itching leading to sleep deprivation, weight gain and low self-esteem.

View profileLoading

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.

AD=atopic dermatitis; BSA=body surface area; CI​​​​​​​=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; LSM=least squares mean; PP-NRS=Peak Pruritus Numerical Rating Scale; Q2W=once every 2 weeks; SCORAD=SCORing Atopic Dermatitis; TCI=topical calcineurin inhibitor.

Prescribing information:
​​​​​​​
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.Bieber T, et al. N Engl J Med 2021;384(12):1101–1112.Bieber T, et al. N Engl J Med 2021;384(12):1101–1112. Supplementary appendix.
PP-CIB-GBR-0058. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​